Cost-effectiveness of proton beam therapy vs. conventional radiotherapy for patients with brain tumors in Sweden : results from a non-randomized prospective multicenter study
(2024) In Cost Effectiveness and Resource Allocation 22(1).- Abstract
Background: This study assessed the cost-effectiveness of proton beam therapy (PBT) compared to conventional radiotherapy (CRT) for treating patients with brain tumors in Sweden. Methods: Data from a longitudinal non-randomized study performed between 2015 and 2020 was used, and included adult patients with brain tumors, followed during treatment and through a one-year follow-up. Clinical and demographic data were sourced from the longitudinal study and linked to Swedish national registers to get information on healthcare resource use. A cost-utility framework was used to evaluate the cost-effectiveness of PBT vs. CRT. Patients in PBT group (n = 310) were matched with patients in CRT group (n = 40) on relevant observables using... (More)
Background: This study assessed the cost-effectiveness of proton beam therapy (PBT) compared to conventional radiotherapy (CRT) for treating patients with brain tumors in Sweden. Methods: Data from a longitudinal non-randomized study performed between 2015 and 2020 was used, and included adult patients with brain tumors, followed during treatment and through a one-year follow-up. Clinical and demographic data were sourced from the longitudinal study and linked to Swedish national registers to get information on healthcare resource use. A cost-utility framework was used to evaluate the cost-effectiveness of PBT vs. CRT. Patients in PBT group (n = 310) were matched with patients in CRT group (n = 40) on relevant observables using propensity score matching with replacement. Costs were estimated from a healthcare perspective and included costs related to inpatient and specialized outpatient care, and prescribed medications. The health outcome was quality-adjusted life-years (QALYs), derived from the EORTC-QLQ-C30. Generalized linear models (GLM) and two-part models were used to estimate differences in costs and QALYs. Results: PBT yielded higher total costs, 14,639 US$, than CRT, 13,308 US$, with a difference of 1,372 US$ (95% CI, -4,914–7,659) over a 58 weeks’ time horizon. Further, PBT resulted in non-significantly lower QALYs, 0.746 compared to CRT, 0.774, with a difference of -0.049 (95% CI, -0.195–0.097). The probability of PBT being cost-effective was < 30% at any willingness to pay. Conclusions: These results suggest that PBT cannot be considered a cost-effective treatment for brain tumours, compared to CRT. Trial registration: Not applicable.
(Less)
- author
- organization
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Brain tumors, Cost-effectiveness analysis, Economic evaluation, Proton therapy, Two-part model
- in
- Cost Effectiveness and Resource Allocation
- volume
- 22
- issue
- 1
- article number
- 66
- publisher
- BioMed Central (BMC)
- external identifiers
-
- scopus:85204013624
- pmid:39272105
- ISSN
- 1478-7547
- DOI
- 10.1186/s12962-024-00577-6
- language
- English
- LU publication?
- yes
- id
- e3d4ebb6-6a36-40f4-92f6-15c69c845a93
- date added to LUP
- 2024-11-12 15:51:18
- date last changed
- 2025-07-09 11:48:09
@article{e3d4ebb6-6a36-40f4-92f6-15c69c845a93,
abstract = {{<p>Background: This study assessed the cost-effectiveness of proton beam therapy (PBT) compared to conventional radiotherapy (CRT) for treating patients with brain tumors in Sweden. Methods: Data from a longitudinal non-randomized study performed between 2015 and 2020 was used, and included adult patients with brain tumors, followed during treatment and through a one-year follow-up. Clinical and demographic data were sourced from the longitudinal study and linked to Swedish national registers to get information on healthcare resource use. A cost-utility framework was used to evaluate the cost-effectiveness of PBT vs. CRT. Patients in PBT group (n = 310) were matched with patients in CRT group (n = 40) on relevant observables using propensity score matching with replacement. Costs were estimated from a healthcare perspective and included costs related to inpatient and specialized outpatient care, and prescribed medications. The health outcome was quality-adjusted life-years (QALYs), derived from the EORTC-QLQ-C30. Generalized linear models (GLM) and two-part models were used to estimate differences in costs and QALYs. Results: PBT yielded higher total costs, 14,639 US$, than CRT, 13,308 US$, with a difference of 1,372 US$ (95% CI, -4,914–7,659) over a 58 weeks’ time horizon. Further, PBT resulted in non-significantly lower QALYs, 0.746 compared to CRT, 0.774, with a difference of -0.049 (95% CI, -0.195–0.097). The probability of PBT being cost-effective was < 30% at any willingness to pay. Conclusions: These results suggest that PBT cannot be considered a cost-effective treatment for brain tumours, compared to CRT. Trial registration: Not applicable.</p>}},
author = {{Sampaio, Filipa and Langegård, Ulrica and de Alva, Patricio Martínez and Flores, Sergio and Nystrand, Camilla and Fransson, Per and Ohlsson-Nevo, Emma and Kristensen, Ingrid and Sjövall, Katarina and Feldman, Inna and Ahlberg, Karin}},
issn = {{1478-7547}},
keywords = {{Brain tumors; Cost-effectiveness analysis; Economic evaluation; Proton therapy; Two-part model}},
language = {{eng}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{Cost Effectiveness and Resource Allocation}},
title = {{Cost-effectiveness of proton beam therapy vs. conventional radiotherapy for patients with brain tumors in Sweden : results from a non-randomized prospective multicenter study}},
url = {{http://dx.doi.org/10.1186/s12962-024-00577-6}},
doi = {{10.1186/s12962-024-00577-6}},
volume = {{22}},
year = {{2024}},
}